Precision Targeted Therapy with BLU-667 for
Publication/Presentation Date
7-1-2018
Abstract
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapies have been designed to target RET; treatment has been limited to multikinase inhibitors (MKI), which can have significant off-target toxicities and limited efficacy. BLU-667 is a highly potent and selective RET inhibitor designed to overcome these limitations.
Volume
8
Issue
7
First Page
836
Last Page
849
ISSN
2159-8290
Published In/Presented At
Subbiah, V., Gainor, J. F., Rahal, R., Brubaker, J. D., Kim, J. L., Maynard, M., Hu, W., Cao, Q., Sheets, M. P., Wilson, D., Wilson, K. J., DiPietro, L., Fleming, P., Palmer, M., Hu, M. I., Wirth, L., Brose, M. S., Ou, S. I., Taylor, M., Garralda, E., … Evans, E. K. (2018). Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer discovery, 8(7), 836–849. https://doi.org/10.1158/2159-8290.CD-18-0338
Disciplines
Medicine and Health Sciences
PubMedID
29657135
Department(s)
Hematology-Medical Oncology Division
Document Type
Article